{
  "ticker": "JNJ",
  "target_date": "2024-12-17",
  "actual_date": "2024-12-17",
  "collected_at": "2025-12-08T11:09:31.840217",
  "price": {
    "open": 139.57,
    "high": 142.3,
    "low": 139.44,
    "close": 142.06141662597656,
    "volume": 10343000,
    "change_1d_pct": 1.78,
    "change_7d_pct": -1.94,
    "change_30d_pct": -6.73
  },
  "technicals": {
    "rsi_14": 25.17,
    "sma_20": 146.34,
    "sma_50": 150.73,
    "macd": -2.643,
    "macd_signal": -2.207,
    "macd_histogram": -0.436,
    "bb_upper": 153.24,
    "bb_lower": 139.44,
    "price_vs_sma20_pct": -2.92,
    "price_vs_sma50_pct": -5.75,
    "volume_ratio": 1.21
  },
  "fundamentals": {
    "market_cap": 488785739776,
    "pe_ratio": 19.58253,
    "forward_pe": 19.13915,
    "price_to_book": 6.157617,
    "price_to_sales": 5.304298,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.37,
    "pct_from_52w_low": 44.21
  },
  "macro": {
    "spy": {
      "price": 597.03,
      "change_1d_pct": -0.41,
      "change_7d_pct": -0.06
    },
    "vix": {
      "level": 15.87,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.39
    },
    "dollar_index": {
      "level": 106.96
    },
    "gold": {
      "price": 2644.4
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "The Take On Tyra Biosciences",
      "source": "SeekingAlpha",
      "datetime": 1734455615,
      "summary": "Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg.",
      "url": "https://finnhub.io/api/news?id=1989fef2977fc61d12075dedb7f7a4cf77cf88bac5a05fa7e2f102baf15ad002"
    },
    {
      "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "source": "MarketWatch",
      "datetime": 1734453060,
      "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=a72455f939d160e5718209532ab171a1278fe4645ef80a44250ebd2119ad6605"
    },
    {
      "headline": "FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC",
      "source": "Yahoo",
      "datetime": 1734441660,
      "summary": "The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.",
      "url": "https://finnhub.io/api/news?id=deab0c819be10ba50c047351dae1a927aac5901c37099ae92750e03c2e968a06"
    },
    {
      "headline": "Johnson & Johnson (NYSE:JNJ) Has A Pretty Healthy Balance Sheet",
      "source": "Yahoo",
      "datetime": 1734436827,
      "summary": "David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...",
      "url": "https://finnhub.io/api/news?id=f3dedc4f888cb1f0a8507aa9edd80f6d944aa54851eccb6bccd06618e242e45c"
    },
    {
      "headline": "Johnson & Johnson - Update on U.S. regulatory review of subcutaneous amivantamab",
      "source": "Finnhub",
      "datetime": 1734429648,
      "summary": "RARITAN - Johnson & Johnson today announced the U.S. Food and Drug Administration has issued a Complete Response Letter for the Biologics License Application for a fixed combination of amivantamab...",
      "url": "https://finnhub.io/api/news?id=29900637138e336b2d4a070076e1dc28cee66d2563b629e460ff78f292ad3c5c"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734042449.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000106/xslF345X05/wk-form4_1734042449.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041779.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000104/xslF345X05/wk-form4_1734041779.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041373.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000102/xslF345X05/wk-form4_1734041373.xml"
    },
    {
      "form": "13F-HR",
      "date": "2024-11-13",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445424000604/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "10-Q",
      "date": "2024-10-23",
      "description": "jnj-20240929.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000096/jnj-20240929.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}